Bausch + Lomb (NYSE:BLCO) Given New $18.00 Price Target at Stifel Nicolaus

Bausch + Lomb (NYSE:BLCO) had its price objective reduced by Stifel Nicolaus from $19.00 to $18.00 in a research report released on Wednesday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

Several other equities analysts have also recently weighed in on BLCO. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Citigroup lowered shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and cut their price target for the company from $24.00 to $22.00 in a research note on Wednesday, December 11th. Morgan Stanley downgraded shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective for the company. in a research report on Monday, December 2nd. Evercore ISI raised shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and boosted their price objective for the company from $19.00 to $25.00 in a research report on Tuesday, October 15th. Finally, Wells Fargo & Company lowered their target price on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Bausch + Lomb has an average rating of “Hold” and a consensus price target of $20.25.

Bausch + Lomb Stock Up 2.8 %

Shares of NYSE:BLCO opened at $17.90 on Wednesday. The company has a 50 day moving average price of $18.38 and a two-hundred day moving average price of $18.13. The company has a market capitalization of $6.31 billion, a PE ratio of -17.04, a PEG ratio of 2.17 and a beta of 0.47. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the company earned $0.22 EPS. The firm’s quarterly revenue was up 18.8% on a year-over-year basis. Analysts forecast that Bausch + Lomb will post 0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Blue Trust Inc. grew its stake in Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock valued at $48,000 after buying an additional 1,004 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in Bausch + Lomb during the fourth quarter worth approximately $72,000. Squarepoint Ops LLC bought a new stake in shares of Bausch + Lomb during the second quarter worth approximately $173,000. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bausch + Lomb in the third quarter valued at approximately $289,000. Finally, Polar Asset Management Partners Inc. bought a new position in shares of Bausch + Lomb during the third quarter worth approximately $289,000. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.